VP of Finance, BigHat Biosciences
Office located in San Mateo, CA
Antibody discovery & engineering platform
Open for applications
Antibody discovery & engineering platform
21-100 employees
Open for applications
Office located in San Mateo, CA
21-100 employees
Company mission
1900 Alameda de Las Pulgas, San Mateo, California 94403, US
Jump to section
Company mission
1900 Alameda de Las Pulgas, San Mateo, California 94403, US
54% employee growth in 12 months
Our take
Melding genetics and code, Bighat Bioscience is a protein therapeutics company that develops antibodies for the medical industry using machine learning and artificial intelligence. Established in 2019, its antibody design capabilities have been tried and tested for numerous use cases, including during the vaccine development race of the pandemic.
The platform has special utility in supporting the creation of drugs for hard-to-treat diseases such as Alzheimer's, which affect large numbers of people. To this end, the company has partnered with leading pharmaceutical companies such as Merck & Co and Amgen to build ML and AI platforms for their drug discovery needs.
Interestingly, BigHat grew its company by 30% in 2022, despite competitors having to downsize, which is a a definitive green flag for its success in the space. It has also won big when it comes to large contractors who see the smoothness and scalability of the platforms it builds, suggesting it will secure more lucrative deals moving forward.
Kirsty
Company Specialist at Welcome to the Jungle
Benefits
- Culture of excellence and growth
- Swift promotions with clear standards
- Autonomy and responsibility
- Fair compensation and recognition
- True work life balance
Funding (last 2 of 3 rounds)
Jul 2022
$75m
SERIES B
Feb 2021
$19m
SERIES A
Total funding: $99.3m
This company has top investors
Leadership
Mark DePristo
(CEO)Currently Advisor at Mirvie and EverlyWell. Previously Head of Genomics Team at Google and Vice President of Informatics at SynapDx.
Peyton Greenside
(CSO)Previously Founding Scientific Advisor at VALIS, Fellow at Schmidt Science Fellows and Quantitative Analyst Intern at Verily Life Sciences.
Theresa Tribble
(Advisor)Currently CEO at Droplet Biosciences. Also founded Landsdowne Labs, and Nebula Industries. Previously Venture Partner at The Engine.